Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.9%

1 terminated/withdrawn out of 106 trials

Success Rate

97.1%

+10.6% vs industry average

Late-Stage Pipeline

7%

7 trials in Phase 3/4

Results Transparency

3%

1 of 34 completed trials have results

Key Signals

8 recruiting1 with results

Enrollment Performance

Analytics

N/A
43(62.3%)
Phase 2
13(18.8%)
Phase 1
6(8.7%)
Phase 4
4(5.8%)
Phase 3
3(4.3%)
69Total
N/A(43)
Phase 2(13)
Phase 1(6)
Phase 4(4)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (106)

Showing 20 of 106 trials
NCT05491811Phase 2Active Not Recruiting

Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation

Role: collaborator

NCT07554885Not ApplicableNot Yet Recruiting

Nutritional Therapy Plus Corticosteroids for Immune Checkpoint Inhibitor-Related Pneumonitis

Role: lead

NCT03240315Active Not Recruiting

Personalized Prediction Strategy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Role: lead

NCT07092137Phase 2Not Yet Recruiting

Nano-crystalline Megestrol Acetate for Anorexia-Cachexia Syndrome in Advanced Lung Cancer

Role: lead

NCT07005999Active Not Recruiting

Interventional Ablation for Early-stage Lung Cancer

Role: lead

NCT06909383Phase 2Not Yet Recruiting

Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm Phase II Clinical Study

Role: lead

NCT06851403Enrolling By Invitation

The Effectiveness and Safety of Dupilumab in Children with Asthma in China: a Real-world Study

Role: lead

NCT06840717Recruiting

Association Between Genetic Polymorphisms and Type 2 Asthma in Children

Role: lead

NCT06772454Recruiting

To Evaluate the Efficacy and Safety of Inhaled Corticosteroids Combined With Bronchodilators and Programmed Death-ligand 1 (PD-L1) Inhibitor Plus Platinum-based Chemotherapy in Patients With Advanced Lung Squamous Cell Carcinoma Complicated With Chronic Obstructive Pulmonary Disease (COPD)

Role: lead

NCT06739928Phase 2Recruiting

Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC

Role: lead

NCT06715956Not Yet Recruiting

Observational Study of Sputum Inflammation Phenotypes and Clinical Outcomes in Non-Cystic Fibrosis Bronchiectasis

Role: lead

NCT06654076Completed

Assessing Diagnostic Methods for Invasive Fungal Disease in Lung Transplant Recipients

Role: lead

NCT06645210Not Yet Recruiting

Multicenter Registration Study on Allergic Bronchopulmonary Aspergillosis

Role: collaborator

NCT06622304Completed

Exploring the Effects of Antihypertensive and Lipid-Lowering Drugs on Inflammatory Cytokine Levels

Role: lead

NCT06622343Completed

Predictive Modeling of Necrotizing Skin Infections in Snakebite Patients

Role: lead

NCT06620068Not Yet Recruiting

Causal Relationship Between Plasma VEGF Family Proteins and Placenta Previa: A Two-Sample Mendelian Randomization Study

Role: lead

NCT06605326Phase 4Completed

Subcutaneous Treprostinil as a Bridge to Lung Transplantation in Severe Pulmonary Hypertension: A Single-Arm Retrospective Study

Role: lead

NCT06497530Phase 2Not Yet Recruiting

Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC

Role: lead

NCT05304897Not ApplicableCompleted

PRP Efficacy and Safety in BPF

Role: lead

NCT06341660Phase 2Recruiting

To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)

Role: lead